Orphan designation: setanaxib Treatment of Alport syndrome, 08/11/2023 Positive
Orphan designation: setanaxib Treatment of Alport syndrome, 08/11/2023 Positive
Orphan designation: setanaxib Treatment of Alport syndrome, 08/11/2023 Positive
Orphan designation: Methyl 4-(2-acetamidoethylsulfanyl)-4-oxobutanoate Treatment of Leigh syndrome, 13/12/2023 Positive
Orphan designation: Allogeneic amniotic fluid-derived mesenchymal stem cells with lung specificity Prevention of primary graft dysfunction following lung transplantation, 13/12/2023 Positive
Orphan designation: golcadomide hydrochloride Treatment of follicular lymphoma, 13/12/2023 Positive
Orphan designation: Selumetinib Treatment of glioma, 13/12/2023 Positive
Orphan designation: cutamesine Treatment of amyotrophic lateral sclerosis, 13/12/2023 Positive
Orphan designation: Ovine polyclonal fragment antigen-binding against ricin Treatment of ricin poisoning, 13/12/2023 Positive
Questions and answers on quality of herbal medicinal products/traditional herbal medicinal products - Revision 7
European Medicines Agency’s data protection notice for grant procedures
Careers at European Medicines Agency (EMA) - Guidance on selection and recruitment